Baxter/Cangene Add Intravascular Hemolysis Warning To WinRho SDF Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
Updated WinRho SDF labeling also warns against falsely elevated blood glucose levels associated with use of the bleeding disorder therapy.
You may also be interested in...
Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says
Mail-Order Pharmacy Not Necessarily Cheaper To Health Plans, Ohio Finds
Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago
Pfizer Torcetrapib Filing To Start ‘Dialogue,’ Not Necessarily Standard Review
Pfizer views its planned filing for its investigational HDL/LDL cholesterol combination therapy torcetrapib/Lipitor as the initiation of a dialogue between the company and FDA, not necessarily the start of a standard review